Reference Detail

Ref Type
PMID
Authors Swaroop Vakkalanka, Seeta Nyayapathy, and Srikant Viswanadha
Title RP6530, a dual PI3K ?/? inhibitor, potentiates ruxolitinib activity in the JAK2-V617F mutant erythroleukemia cell lines
Journal Cancer Res
Vol
Issue
Date
URL http://cancerres.aacrjournals.org/content/75/15_Supplement/2704.short
Abstract Text Cancer Res August 1, 2015 75; 2704

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Therapy Description
Drug Name Trade Name Synonyms Drug Classes Drug Description
Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
JAK2 V617F acute myeloid leukemia sensitive RP6530 + Ruxolitinib Preclinical Actionable In a preclinical study, RP6530 worked synergistically with Jakafi (ruxolitinib) to inhibit proliferation of Jakafi (ruxolitinib)-resistant erythroleukemia cell lines carrying JAK2 V617F mutation ( Cancer Res August 1, 2015 75; 2704 ). detail...